PCI-CURE Study Design CURE PCI-CURE N = 2,658 patients undergoing PCI Pretreatment Open-label thienopyridine PLACEBO + ASA * N = 1345 End of follow-up PCI 30 days post PCI Up to 12 months R after randomization Open-label thienopyridine CLOPIDOGREL + ASA * N = 1313 Pretreatment * In combination with standard therapy Mehta, SR. et al for the CURE Trial Investigators. N Engl J Med. 2001;345:494-502. PCI-CURE Overall Long-Term Results Composite of cardiovascular death or MI from randomization to end of follow-up 0.15 12.6% Placebo + ASA* Cumulative Hazard Rate 0.10 8.8% Clopidogrel + ASA* 0.05 31% RRR P = 0.002 N = 2658 0.0 0 100 200 300 400 Days of follow-up * In combination with standard therapy Mehta, SR. et al for the CURE Trial Investigators. Lancet. August 2001.
Pages to are hidden for
"Study Design"Please download to view full document